{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:22:46Z","timestamp":1773523366163,"version":"3.50.1"},"reference-count":6,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,12,10]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Papulopustular eruptions are the most common cutaneous adverse effect of epidermal growth factor receptor (EGFR) inhibitors, typically arising within the first month of therapy. We describe an unusual late-onset presentation. A middle-aged woman with EGFR-positive metastatic non-small-cell lung carcinoma had received gefitinib 250\u2009mg daily for 2.5 years. 15 days before the consultation, she developed painful, erythematous papules and pustules confined to the right face, trunk and thighs, together with paronychia of the right great toe. Skin biopsy revealed a subcorneal neutrophilic pustule and a mixed perivascular and perifollicular infiltrate, confirming an EGFR-inhibitor\u2013related folliculitis. A diagnosis of unilateral papulopustular eruption and paronychia to gefitinib was made. She had significant improvement with doxycycline 100\u2009mg twice daily and gefitinib was continued. This case highlights that late-onset, unilateral PRIDE syndrome manifestations can occur and are manageable without interrupting effective anticancer therapy.<\/jats:p>","DOI":"10.1136\/bcr-2025-268366","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T05:10:11Z","timestamp":1766985011000},"page":"e268366","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Gefitinib-induced unilateral papulopustular dermatosis: an uncommon presentation"],"prefix":"10.1136","volume":"18","author":[{"given":"Priya","family":"yadav","sequence":"first","affiliation":[{"name":"Dermatology and Venereology, AIIMS, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3378-5492","authenticated-orcid":false,"given":"Shreya K","family":"Gowda","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, AIIMS, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3314-1734","authenticated-orcid":false,"given":"Rhea","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, AIIMS, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samudra","family":"Basu","sequence":"additional","affiliation":[{"name":"Department of Pathology, AIIMS New Delhi, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somesh","family":"Gupta","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology, AIIMS, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"key":"2025122821100424000_18.12.e268366.1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities","volume":"37 Suppl 4","author":"Yarden","year":"2001","journal-title":"Eur J Cancer Oxf Engl"},{"key":"2025122821100424000_18.12.e268366.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-0436.2007.00238.x"},{"key":"2025122821100424000_18.12.e268366.3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/postmj\/qgae104","article-title":"A linear and reticulate crusted keratotic papulopustular eruption: a rare presentation of PRIDE (Papulopustules and\/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) complex","volume":"101","author":"Gowda","year":"2024","journal-title":"Postgrad Med J"},{"key":"2025122821100424000_18.12.e268366.4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","article-title":"NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer","volume":"7 Suppl 1","author":"Burtness","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"2025122821100424000_18.12.e268366.5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/etm.2015.2881","article-title":"Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature","volume":"11","author":"Ferrazzi","year":"2016","journal-title":"Exp Ther Med"},{"key":"2025122821100424000_18.12.e268366.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70311-0"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-268366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T05:10:12Z","timestamp":1766985012000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-268366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":6,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,28]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bcr-2025-268366"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-268366","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}